Trial Profile

An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darolutamide (Primary)
Indications Prostate cancer
Focus Adverse reactions; Registrational
Acronyms ARAMIS Rollover
Sponsors Bayer

Most Recent Events

10 Apr 2025 Planned number of patients changed from 730 to 402.
03 Jul 2024 Planned End Date changed from 25 Jun 2025 to 26 Jun 2028.
03 Jul 2024 Planned primary completion date changed from 25 Jun 2025 to 26 Jun 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com